Clinical trials: Inadequate Response
Rheumatoid Arthritis
The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis
This is a randomized, double-blind, double-dummy, tofacitinib-parallel-group, phase 2A study to assess the safety and efficacy of TLL-018 in active rheumatoid arthritis subject who had an inadequate response or intolerance to…
- Trial name
- NCT05133297
- Testing
- TLL-018, Tofacitinib
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Migraine Prophylaxis
An Efficacy and Safety Study of Fremanezumab in Adults With Migraine
The purpose of this study is to evaluate the efficacy, safety, and tolerability of monthly and quarterly subcutaneous (sc) injections of fremanezumab compared with sc injections of placebo in participants with chronic migraine…
- Trial name
- FOCUS (NCT03308968)
- Testing
- Fremanezumab
- Where
- 113 sites in United States, Belgium and 12 more
- Volunteers
- 838 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Primary Biliary Cholangitis
Phase I/II Trial of Human Umbilical Cord Mesenchymal Stromal Cells for UDCA-Refractory Primary Biliary Cholangitis
This phase I/II clinical trial evaluates human umbilical cord-derived mesenchymal stromal cell (hUC-MSC) injection in patients with primary biliary cholangitis (PBC).
- Trial name
- MSC-PBC-I/II (NCT07795151)
- Testing
- Standard background therapy, hUC-MSC Dose Level 1, hUC-MSC Dose Level 2
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Beijing 302 Hospital
Rheumatoid Arthritis
Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis
The purpose of this study is to prove that efficacy, safety and immunogenicity of BCD-020 is equivalent to MabThera when used in combination with methotrexate for the treatment of patient with rheumatoid arthritis
- Trial name
- BIORA (NCT01759030)
- Testing
- Rituximab
- Where
- 40 sites in Belarus, India and 2 more
- Volunteers
- 181 people
- Sponsor
- Biocad
Colitis, Ulcerative
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission.
- Trial name
- NCT05076175
- Testing
- Ozanimod
- Where
- 91 sites in United States, Australia and 11 more
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs
This observational study will evaluate in clinical practice the change in Disease Activity Score (DAS28) in patients with rheumatoid arthritis and an inadequate response to DMARDs who are initiated on treatment with…
- Trial name
- NCT01388309
- Where
- 4 sites in Slovakia
- Volunteers
- 64 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Psoriatic
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severely Active Psoriatic Arthritis Subjects with Inadequate Response to Disease Modifying anti-Rheumatic Drug Therapy
- Trial name
- NCT00646178
- Testing
- adalimumab
- Volunteers
- 102 people
- Sponsor
- Abbott
Major Depressive Disorder
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838681
- Testing
- Brexpiprazole, ADT
- Where
- 107 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,986 people
- Sponsor
- H. Lundbeck A/S
Psoriasis
Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments
The purpose of this study is to evaluate safety and efficacy of etanercept in patients with psoriasis who had an unsatisfactory response to adalimumab and infliximab.
- Trial name
- NCT00967538
- Testing
- etanercept 50 mg
- Where
- 16 sites in Canada
- Volunteers
- 89 people
- Sponsor
- Innovaderm Research Inc.
Anemia
A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India
The purpose of this study is to evaluate the safety and effectiveness of luspatercept in participants who require regular blood cell transfusions due to b-thalassemia and myelodysplastic syndromes in India
- Trial name
- NCT05891249
- Testing
- Luspatercept
- Where
- 9 sites in India
- Volunteers
- 85 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
The purpose of this study is to evaluate the efficacy and safety of T-614 versus placebo when added to ongoing, stable-dose methotrexate therapy in patients with persistently active rheumatoid arthritis
- Trial name
- NCT00965757
- Testing
- T-614
- Where
- 72 sites in Japan
- Volunteers
- 253 people
- Sponsor
- Eisai Co., Ltd.
Rheumatoid Arthritis
A Study in Participants With Rheumatoid Arthritis
The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis in participants with an inadequate response to one or more tumor necrosis factor-alpha (TNF-α)…
- Trial name
- FLEX V (NCT01202773)
- Testing
- LY2127399
- Where
- 201 sites in United States, Argentina and 17 more
- Volunteers
- 456 people
- Sponsor
- Eli Lilly and Company
Psoriatic Arthritis
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.
- Trial name
- OPAL BEYOND (NCT01882439)
- Testing
- Tofacitinib
- Where
- 125 sites in United States, Australia and 12 more
- Volunteers
- 395 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
This is a randomized, double-blind study comparing ABT-494 to placebo in Japanese participants with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic disease-modifying…
- Trial name
- SELECTSUNRISE (NCT02720523)
- Testing
- Upadacitinib
- Where
- 50 sites in Japan
- Volunteers
- 197 people
- Sponsor
- AbbVie
Infertility
Study of Optimal Posology of Gonadotrophins in Patients With Insufficient Ovarian Response Due to Age
In In vitro fertilization (IVF) treatment, poor responder patients of more than 38 years old are randomized prospectively into two dosages of gonadotrophins. The outcome of treatment will be analyzed.
- Trial name
- NCT00575302
- Testing
- Gonal-f®: follitropin alpha
- Where
- 4 sites in Belgium
- Volunteers
- 400 people
- Sponsor
- Centre Hospitalier Chretien
Psoriasis
PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept
The purpose of this study is to test the safety and effectiveness of infliximab in patients with plaque psoriasis who have been receiving the drug etanercept for treatment of their plaque psoriasis for at least four months…
- Trial name
- NCT00527072
- Testing
- infliximab
- Volunteers
- 217 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Benign Prostatic Hyperplasia (BPH), Benign Prostatic Enlargement (BPE)
Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy
The injection of botulinum neurotoxin A into the prostate represents an alternative, minimal invasive treatment in patient with lower urinary tract symptoms (LUTS) associated to benign prostatic hyperplasia (BPH).
- Trial name
- NCT01566292
- Testing
- BOTOX
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Catholic University of the Sacred Heart
Rheumatoid Arthritis
A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy
This study will assess the safety and efficacy of rituximab combined with MTX in participants with active rheumatoid arthritis (RA) who have had an inadequate response to anti-Tumor Necrosis (TNF) alpha therapy.
- Trial name
- NCT00468546
- Testing
- MabThera/Rituxan, Methotrexate
- Where
- 115 sites in United States, Belgium and 9 more
- Volunteers
- 520 people
- Sponsor
- Hoffmann-La Roche
Neuralgia, Postherpetic
A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
The purpose of this study is evaluate the difference between two doses of gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, on pain associated with post-herpetic neuralgia.
- Trial name
- NCT00617461
- Testing
- GEn 1200mg/day, GEn 3600mg/day
- Where
- 53 sites in United States, Germany
- Volunteers
- 96 people
- Sponsor
- XenoPort, Inc.
Arthritis, Rheumatoid
A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
This is a randomized, double-blind, parallel group, multicenter clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of LBAL compared to Humira® in subjects with active Rheumatoid Arthritis despite…
- Trial name
- NCT02746380
- Testing
- LBAL, Humira®
- Where
- 2 sites in Japan, South Korea
- Volunteers
- 383 people
- Sponsor
- LG Life Sciences